References
- Commonwealth Department of Health, Housing and Community Services. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. August, 1992. Australian Government Publishing Service, CanberraAustralia
- Tarn TYH, Dix Smith M. ISPOR Connections 2004; 10((4))
- Wang H, Xu T, Xu J. Factors contributing to high costs and inequality in China's health care system. Journal of the American Medical Assiciation 2007; 298((16))1928–1930.
- Moon S, Shin J. Performance of universal health insurance: lessons from South Korea. World Health & Population 2007; 9((2))95–113.
- Ikeda S, Ikegami N, Oliver AJ, Ikeda M. A case for the adoption of pharmacoeconomic guidelines in Japan. Pharmacoeconomics. 1996; 10((6))546–551.
- Centre of Pharmacoeconomic Evaluation. China Pharmacoeconomic Evaluation Guidelines. 2006. Chinese Medical Doctor Association, BeijingChina.
- Yang BM, Bae EY, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Affairs 2008; 27((1))179–187.
- Tarn TYH, Hu SL, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value in Health 2008; 11((Suppl 1))S137–S155.
- Davey P, Lynch M, Makino K. Drug pricing and reimbursement issues using health economics and outcomes research in drug reimbursement – which way forward for the Asian region. Proceedings of ISPOR 2nd Asia-Pacific Conference, ShanghaiChina, 2006.
- Doherty J, Kamae I, Lee K, et al. What's Next for Pharmacoeconomics and Outcomes Research in Asia?. Value in Health 2004; 7((2))118–132.